The adenovirus E1B-55K oncoprotein induces SUMO modification of p53

被引:48
|
作者
Muller, Stefan [1 ]
Dobner, Thomas [2 ]
机构
[1] Max Planck Inst Biochem, Dept Mol Cell Biol, D-82152 Martinsried, Germany
[2] Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-2000 Hamburg, Germany
关键词
SUMO; adenovirus; p53; E1B-55K; ubiquitin;
D O I
10.4161/cc.7.6.5495
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The ability of adenovirus to induce cell transformation depends on the E1A and E1B-55K oncoproteins. While E1A functionally inactivates the retinoblastoma tumour suppressor, E1B-55K primarily interferes with the function of p53. In adenovirus transformed cells E1B-55K can directly affect p53-dependent transactivation. In virus-infected cells E1B-55K additionally cooperates with the viral E4orf6 protein to induce ubiquitin-dependent degradation of p53. Here we unravel a novel activity of E1B-55K by demonstrating that it drastically stimulates the post-translational modification of p53 by the ubiquitin-like SUMO modifier. Consistent with this finding the extent of p53 SUMOylation is highly elevated in adenovirus transformed cell lines. E1B-55K-mediated SUMOylation depends on the direct interaction of E1B-55K with p53 and additionally requires SUMO modification of E1B-55K. These data suggest that E1B-55K exploits both ubiquitin and ubiquitin-like systems to target host cell proteins and thus shed new light on the molecular mechanisms of E1B-55K function. Moreover, the data expand the emerging concept of dual-specificity factors that act in both the SUMO and ubiquitin pathway and identify E1B-55K as the first viral protein that shares this dual activity.
引用
收藏
页码:754 / 758
页数:5
相关论文
共 50 条
  • [31] Analyses of single-amino-acid substitution mutants of adenovirus type 5 E1B-55K protein
    Shen, YQ
    Kitzes, G
    Nye, JA
    Fattaey, A
    Hermiston, T
    JOURNAL OF VIROLOGY, 2001, 75 (09) : 4297 - 4307
  • [32] Infection with E1B-mutant adenovirus stabilizes p53 but blocks p53 acetylation and activity through E1A
    I Savelyeva
    M Dobbelstein
    Oncogene, 2011, 30 : 865 - 875
  • [33] Analyses of single amino acid substitution mutants of adenovirus type 5 E1B-55K protein.
    Shen, YQ
    Kitzes, G
    Nye, J
    Fattaey, A
    Hermiston, T
    CLINICAL CANCER RESEARCH, 2000, 6 : 4568S - 4568S
  • [34] Adenovirus E1B 55-Kilodalton Protein Is a p53-SUMO1 E3 Ligase That Represses p53 and Stimulates Its Nuclear Export through Interactions with Promyelocytic Leukemia Nuclear Bodies
    Pennella, Mario A.
    Liu, Yue
    Woo, Jennifer L.
    Kim, Chongwoo A.
    Berk, Arnold J.
    JOURNAL OF VIROLOGY, 2010, 84 (23) : 12210 - 12225
  • [35] Adeno-associated virus Rep78 restricts adenovirus E1B55K-mediated p53 nuclear exportation
    Wang, Jingjing
    Li, Wenjuan
    Wang, Ran
    Xue, Jinglun
    Chen, Jinzhong
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2013, 45 (02) : 135 - 140
  • [36] Adenovirus E1B 55-kilodalton oncoprotein binds to Daxx and eliminates enhancement of p53-dependent transcription by Daxx
    Zhao, LY
    Colosimo, AL
    Liu, Y
    Wan, YP
    Liao, DQ
    JOURNAL OF VIROLOGY, 2003, 77 (21) : 11809 - 11821
  • [37] Proteasome-Dependent Degradation of Daxx by the Viral E1B-55K Protein in Human Adenovirus-Infected Cells
    Schreiner, Sabrina
    Wimmer, Peter
    Sirma, Hueseyin
    Everett, Roger D.
    Blanchette, Paola
    Groitl, Peter
    Dobner, Thomas
    JOURNAL OF VIROLOGY, 2010, 84 (14) : 7029 - 7038
  • [38] The adenovirus oncoprotein E1a stimulates binding of transcription factor ETF to transcriptionally activate the p53 gene
    Hale, TK
    Braithwaite, AW
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (34) : 23777 - 23786
  • [39] Efficient induction of cell death by adenoviruses requires binding of E1b55k and p53
    Dix, BR
    O'Carroll, SJ
    Myers, CJ
    Edwards, SJ
    Braithwaite, AW
    CANCER RESEARCH, 2000, 60 (10) : 2666 - 2672
  • [40] E1B 55K sequesters WT1 along with p53 within a cytoplasmic body in adenovirus-transformed kidney cells
    Maheswaran, S
    Englert, C
    Lee, SB
    Ezzel, RM
    Settleman, J
    Haber, DA
    ONCOGENE, 1998, 16 (16) : 2041 - 2050